查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1504207

臨床試驗的市場規模，佔有率，預測，趨勢分析:各類服務，各治療領域，不同階段，各終端用戶-2031年前的全球預測

Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service Therapeutic Area Phase, End User - Global Forecast to 2031
出版日期: | 出版商: Meticulous Research | 英文 230 Pages | 商品交期: 5-7個工作天內

價格

到2031年，臨床試驗市場預計將達到1022億美元，2024年至2031年的複合年增長率為7.2%。

本報告在對市場情景進行廣泛的二次研究、初步研究和詳細分析後，對主要行業促進因素、市場限制因素、市場促進因素和課題進行了分析。臨床試驗市場的成長是由對罕見疾病的日益關注、個人化醫療的日益採用、研發成本的上升以及透過改進臨床試驗招募流程提高參與者保留率所推動的。然而，更長的臨床試驗持續時間、更嚴格的法規以及不斷變化的法律增加了臨床試驗的複雜性，正在限制該市場的成長。

此外，利用醫療物聯網 (IoMT)、基於雲端的藥物警戒系統以及將人工智慧整合到臨床試驗中的以患者為中心的臨床試驗的進展預計將為市場利益相關者提供成長機會。然而，缺乏熟練和專業的公司進行臨床試驗、臨床試驗方案的複雜性以及缺乏多種族的參與是臨床試驗市場的主要課題。我們還將數位健康技術引入臨床試驗，在臨床試驗中使用可穿戴技術、臨床試驗自動化、臨床試驗分散化、用於患者豐富和招募的AI建模和預測以及使用AI分析的臨床試驗等都是值得注意的。

目錄

第1章 簡介

第2章 調查手法

第3章 摘要整理

第 4 章市場洞察

  • 摘要
  • 促進因素
    • 越來越關注罕見疾病
    • 越來越多採用個人化醫療
    • 研發費用增加
    • 透過改善臨床試驗的招募流程來確保參與者的安全
  • 抑制因素
    • 臨床試驗過程漫長
    • 由於嚴格的法規和法律變化，臨床試驗變得更加複雜
  • 機會
    • 利用醫療物聯網 (IoMT) 進行以病人為中心的臨床試驗
    • 基於雲端的藥物警戒系統的進展
    • 將人工智慧融入臨床試驗地點選擇
  • 作業
    • 缺乏熟練的臨床試驗專家
    • 臨床試驗方案的複雜性
    • 缺乏多族群的參與
  • 趨勢
    • 將數位健康技術引入臨床試驗
    • 穿戴式科技在臨床試驗的應用
    • 臨床試驗自動化
    • 臨床試驗的分散化
    • 患者豐富和招募的人工智慧建模和預測
    • 使用人工智慧進行臨床試驗分析
  • 因素分析
  • 監理分析
    • 美國
    • 加拿大
    • 歐洲
    • 中國
    • 日本
    • 印度
    • 拉丁美洲
    • 中東
  • 個案研究
  • 波特五力分析

第五章臨床試驗市場：分階段評估

  • 摘要
  • 臨床前研究
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第六章臨床試驗市場：依服務類型評估

  • 服務概覽
  • 諮詢服務
  • 安全與監理合規服務
  • 設施/病患支援服務
  • 行銷審批相關服務
  • 資料管理服務
  • 分散臨床試驗 (DCT)/虛擬臨床試驗 (VCT) 服務
  • 病患招募服務
  • 統計分析服務
  • 生物分析服務
  • 其他服務

第七章臨床試驗市場：依治療領域評估

  • 摘要
  • 癌症領域
  • 傳染病
  • 循環系統
  • 新陳代謝/內分泌
  • 中樞神經系統 (CNS)/神經病學
  • 皮膚科
  • 骨科/風濕科
  • 罕見疾病
  • 胃腸病學/肝病學
  • 呼吸系統
  • 女性健康
  • 泌尿科
  • 心理健康
  • 眼科

第8章 臨床試驗市場:各終端用戶評估

  • 概要
  • 醫藥品·生物科技企業
  • 醫療設備企業
  • 其他的終端用戶

第9章 臨床試驗市場:各終端用戶評估

  • 概要
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 波蘭
    • 比利時
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 南美
    • 巴西
    • 墨西哥
    • 其他南美國家
  • 中東·非洲

第10章 競爭分析

  • 概要
  • 主要成長策略
  • 競爭基準
  • 競爭儀表板
    • 產業領導者
    • 市場差異化要素
    • 領先企業
    • 新興企業
  • 主要企業的市場佔有率分析/市場排行榜(2023年)

第11章 企業簡介(產業概要，財務概要，產品系列，策略性展開，SWOT分析*)

  • Laboratory Corporation of America Holdings
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • IQVIA Inc.
  • Parexel International Corporation
  • Syneos Health
  • ICON plc
  • WuXi AppTec Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • Fortrea Inc.
  • Celerion Inc.
  • Novotech Health Holdings
  • SGS Societe Generale de Surveillance SA.
  • CTI Clinical Trial and Consulting, Inc.
  • Linical USA, Inc.

(註：提供前 5 名公司 SWOT 分析)

第12章 附錄

Product Code: MRHC - 1041251

Clinical Trials Market Size, Share, Forecast, & Trends Analysis by Service (Consulting, Patient Recruitment, Data Management, Regulatory, Site Support), Therapeutic Area (Oncology, Cardiology, Diabetes, Dermatology), Phase, End User-Global Forecast to 2031

The clinical trials market is projected to reach $102.20 billion by 2031, at a CAGR of 7.2% from 2024 to 2031.

After extensive secondary and primary research and an in-depth analysis of the market scenario, the report provides an analysis of key industry drivers, restraints, opportunities, and challenges. The growth of the clinical trials market is driven by the increasing focus on rare diseases, the rising adoption of personalized medicine, increasing research & development expenditures, and improvements in the clinical trials recruitment process resulting in improved participant retention. However, the extended durations of clinical trials, stringent regulations, and changing laws increasing the complexity of clinical trials restrain the growth of this market.

Furthermore, patient-centric clinical trials using the Internet of Medical Things (IoMT), advancements in cloud-based systems for pharmacovigilance, and the integration of AI into clinical trials are expected to offer growth opportunities for market stakeholders. However, the lack of skilled professionals to conduct clinical trials, the complexity of clinical trial protocols, and the lack of participation from several ethnic groups are major challenges in the clinical trials market. Also, the incorporation of digital health technologies into clinical trials, the use of wearable technologies for clinical trials, automation of clinical trials, decentralized clinical trials, AI modeling and forecasting of patient enrichment and recruitment, and AI-enabled clinical trial analytics are prominent trends in the clinical trials market.

The report offers a competitive landscape based on an extensive assessment of the leading players' product portfolios, geographic presence, and key strategies adopted over the last four years (2020-2024). The key players operating in the clinical trials market are Laboratory Corporation of America Holdings (U.S.), Medpace, Inc. (U.S.), Charles River Laboratories International, Inc. (U.S.), IQVIA Inc. (U.S.), Parexel International Corporation (U.S.), Syneos Health (U.S.), ICON plc (Ireland), WuXi AppTec Co., Ltd. (China), Thermo Fisher Scientific Inc. (U.S.), Fortrea Inc. (U.S.), Celerion Inc. (U.S.), Novotech Health Holdings (Australia), SGS Societe Generale de Surveillance SA. (Switzerland), CTI Clinical Trial and Consulting, Inc. (U.S.), and Linical USA, Inc. (U.S.).

Based on phase, the clinical trials market is segmented into pre-clinical trials, phase I, phase II, phase III, and phase IV. In 2024, the phase III segment is expected to account for the largest share of 68.4% of the clinical trials market. Phase III clinical trials use large groups of people to observe the adverse effects of treatments and utilize sophisticated services for studying the efficacy and safety of drugs. Such factors have contributed to the largest share of this segment. Additionally, many pharmaceutical and biotechnology companies outsource their phase III clinical trials to service providers, supporting the segment's large share.

Among all the therapeutic areas studied in this report, in 2024, the oncology segment is expected to account for the largest share of the clinical trials market. The largest share of this segment is attributed to the high prevalence of cancer, government support to develop new cancer medicines, high healthcare expenditure for cancer, and an increasing number of clinical trials in oncology. For instance, according to a November 2023 report by Pharmaceutical Research and Manufacturers of America (U.S.), 1,600 treatments and vaccines are in development for cancer. Such developments are expected to support the segment's large share.

Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the clinical trials market. The segment's large share is attributed to the increasing demand for innovative therapies for various diseases. Pharmaceutical & biotechnology companies' high investments in R&D for the development of new drugs and therapies are driving clinical trials, contributing to the segment's large share.

An in-depth analysis of the geographical scenario in the clinical trials market provides detailed qualitative and quantitative insights into five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of 41.6% of the clinical trials market. North America's significant market share is attributed to increasing R&D investments, the rising adoption of new technologies in clinical trials, and the presence of key market players in this region. For instance, in March 2024, the Laboratory Corporation of America Holdings (U.S.) launched pTau217, a biomarker test for accelerating the diagnosis of Alzheimer's disease, which is also used for clinical trials. Additionally, according to the National Library of Medicine (U.S.), approximately 149,999 clinical trial studies were registered in the U.S. as of April 2024.

Scope of the Report:

Clinical Trials Market Assessment-by Phase

  • Pre-clinical Trial
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Clinical Trials Market Assessment-by Service Type

  • Consulting Services
  • Safety & Regulatory Compliance Services
  • Site & Patient Support Services
  • Marketing Authorization Holder Related Services
  • Data Management Services
  • Decentralized Clinical Trials (DCT)/Virtual Clinical Trials (VCT) Services
  • Patient Recruitment Services
  • Statistical Analysis Services
  • Bioanalytical services
  • Other Services

Note: Other services include sample storage & aliquoting services, laboratory services, research review services, manufacturing services, cold chain logistics & management services, and In-Country Clinical Caretaker (ICCC) Services.

Clinical Trials Market Assessment-by Therapeutic Area

  • Oncology
  • Infectious Diseases
  • Cardiology
  • Metabolism & Endocrinology
  • Central Nervous System (CNS)/Neurology
  • Dermatology
  • Orthopedic & Rheumatology
  • Rare Diseases
  • Gastroenterology & Hepatology
  • Respiratory
  • Women's Health
  • Urology
  • Mental Health
  • Ophthalmology

Clinical Trials Market Assessment-by End User

  • Pharmaceutical & Biotechnology Companies
  • Medical Device Companies
  • Other End Users

Note: Other end users include Contract Research Organizations (CROs), academic & research institutions, and government organizations.

Clinical Trials Market Assessment-by Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Poland
    • Belgium
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa

TABLE OF CONTENTS

1. Introduction

  • 1.1. Market Definition & Scope
  • 1.2. Market Ecosystem
  • 1.3. Currency and Limitations
  • 1.4. Key Stakeholders

2. Research Methodology

  • 2.1. Research Approach
  • 2.2. Process of Data Collection & Validation
    • 2.2.1. Secondary Research
    • 2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
  • 2.3. Market Sizing and Forecasting
    • 2.3.1. Market Size Estimation Approach
    • 2.3.2. Growth Forecast Approach
    • 2.3.3. Market Share Analysis
  • 2.4. Assumptions for the Study

3. Executive Summary

4. Market Insights

  • 4.1. Overview
  • 4.2. Drivers
    • 4.2.1. Increasing Focus on Rare Diseases
    • 4.2.2. Rise in Adoption of Personalized Medicine
    • 4.2.3. Increasing Research and Development Expenditure
    • 4.2.4. Improvement in Recruitment Process in Clinical Trials Resulting in Retention of Participants
  • 4.3. Restraints
    • 4.3.1. The Time-consuming Process of Clinical Trials
    • 4.3.2. Stringent Regulations and Changing Laws Increasing the Complexity of Clinical Trials
  • 4.4. Opportunities
    • 4.4.1. Patient-centric Clinical Trials Using Internet of Medical Things (IoMT)
    • 4.4.2. Advancements in Cloud-based Systems for Pharmacovigilance
    • 4.2.3. Integration of AI in Clinical Trial Site Selection
  • 4.5. Challenges
    • 4.5.1. Lack of Skilled Professionals in Clinical Trial
    • 4.5.2. Complexity in Clinical Trial Protocols
    • 4.5.3. Lack of Participation from Several Ethnic Groups
  • 4.6. Trends
    • 4.6.1. Incorporating Digital Health Technologies into Clinical Trial
    • 4.6.2. Use of Wearable Technology for Clinical Trials
    • 4.6.3. Automated Clinical Trials
    • 4.6.4. Decentralized Clinical Trials
    • 4.6.5. AI Modeling and Forecasting Patient Enrichment & Recruitment
    • 4.6.6. AI-enabled Clinical Trial Analytics
  • 4.7. Factor Analysis
  • 4.8. Regulatory Analysis
    • 4.8.1. U.S.
    • 4.8.2. Canada
    • 4.8.3. Europe
    • 4.8.4. China
    • 4.8.5. Japan
    • 4.8.6. India
    • 4.8.7. Latin America
    • 4.8.8. Middle East
  • 4.9. Case Studies
  • 4.10. Porter's Five Forces Analysis

5. Clinical Trials Market Assessment-by Phase

  • 5.1. Overview
  • 5.2. Pre-clinical Trial
  • 5.3. Phase I
  • 5.4. Phase II
  • 5.5. Phase III
  • 5.6. Phase IV

6. Clinical Trials Market Assessment-by Service Type

  • 6.1. Overview
  • 6.2. Consulting Services
  • 6.3. Safety & Regulatory Compliance Services
  • 6.4. Site & Patient Support Services
  • 6.5. Marketing Authorization Holder Related Services
  • 6.6. Data Management Services
  • 6.7. Decentralized Clinical Trials (DCT)/Virtual Clinical Trials (VCT) Services
  • 6.8. Patient Recruitment Services
  • 6.9. Statistical Analysis Services
  • 6.10. Bioanalytical Services
  • 6.11. Other Services

7. Clinical Trials Market Assessment-by Therapeutic Area

  • 7.1. Overview
  • 7.2. Oncology
  • 7.3. Infectious Diseases
  • 7.4. Cardiology
  • 7.5. Metabolism & Endocrinology
  • 7.6. Central Nervous System (CNS)/Neurology
  • 7.7. Dermatology
  • 7.8. Orthopedic and Rheumatology
  • 7.9. Rare Diseases
  • 7.10. Gastroenterology & Hepatology
  • 7.11. Respiratory
  • 7.12. Women's Health
  • 7.13. Urology
  • 7.14. Mental Health
  • 7.15. Ophthalmology

8. Clinical Trials Market Assessment-by End User

  • 8.1. Overview
  • 8.2. Pharmaceuticals & Biotechnology Companies
  • 8.3. Medical Device Companies
  • 8.4. Other End Users

9. Clinical Trials Market Assessment-by End User

  • 9.1. Overview
  • 9.2. North America
    • 9.2.1. U.S.
    • 9.2.2. Canada
  • 9.3. Europe
    • 9.3.1. Germany
    • 9.3.2. France
    • 9.3.3. U.K.
    • 9.3.4. Italy
    • 9.3.5. Spain
    • 9.3.6. Poland
    • 9.3.7. Belgium
    • 9.3.8. Rest of Europe
  • 9.4. Asia-Pacific
    • 9.4.1. Japan
    • 9.4.2. China
    • 9.4.3. India
    • 9.4.4. Australia
    • 9.4.5. South Korea
    • 9.4.6. Rest of Asia-Pacific
  • 9.5. Latin America
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America
  • 9.6. Middle East & Africa

10. Competition Analysis

  • 10.1. Overview
  • 10.2. Key Growth Strategies
  • 10.3. Competitive Benchmarking
  • 10.4. Competitive Dashboard
    • 10.4.1. Industry Leaders
    • 10.4.2. Market Differentiators
    • 10.4.3. Vanguards
    • 10.4.4. Emerging Companies
  • 10.5. Market Share Analysis/Market Rankings of Key Players (2023)

11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis*)

  • 11.1. Laboratory Corporation of America Holdings
  • 11.2. Medpace, Inc.
  • 11.3. Charles River Laboratories International, Inc.
  • 11.4. IQVIA Inc.
  • 11.5. Parexel International Corporation
  • 11.6. Syneos Health
  • 11.7. ICON plc
  • 11.8. WuXi AppTec Co., Ltd.
  • 11.9. Thermo Fisher Scientific Inc.
  • 11.10. Fortrea Inc.
  • 11.11. Celerion Inc.
  • 11.12. Novotech Health Holdings
  • 11.13. SGS Societe Generale de Surveillance SA.
  • 11.14. CTI Clinical Trial and Consulting, Inc.
  • 11.15. Linical USA, Inc.

(Note: SWOT analyses of the top 5 companies will be provided.)

12. Appendix

  • 12.1. Available Customization
  • 12.2. Related Reports

LIST OF TABLES

  • Table 1 Global Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 2 Global Pre-clinical Trial Market, by Country/Region, 2022-2031 (USD Million)
  • Table 3 Global Phase I Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 4 Global Phase II Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 5 Global Phase III Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 6 Global Phase IV Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 7 Global Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 8 Global Clinical Trials Consulting Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 9 Global Clinical Trials Safety & Regulatory Compliance Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 10 Global Clinical Trials Site & Patient Support Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 11 Global Clinical Trials Marketing Authorization Holder Related Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 12 Global Clinical Trials Data Management Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 13 Global Decentralized Clinical Trials (DCT) / Virtual Clinical Trials (VCT) Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 14 Global Clinical Trials Patient Recruitment Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 15 Global Clinical Trials Statistical Analysis Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 16 Global Clinical Trials Bioanalytical Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 17 Global Other Clinical Trials Services Market, by Country/Region, 2022-2031 (USD Million)
  • Table 18 Global Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 19 Global Clinical Trials Market for Oncology, by Country/Region, 2022-2031 (USD Million)
  • Table 20 Global Clinical Trials Market for Infectious Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 21 Global Clinical Trials Market for Cardiology, by Country/Region, 2022-2031 (USD Million)
  • Table 22 Global Clinical Trials Market for Metabolism & Endocrinology, by Country/Region, 2022-2031 (USD Million)
  • Table 23 Global Clinical Trials Market for Central Nervous System (CNS)/Neurology, by Country/Region, 2022-2031 (USD Million)
  • Table 24 Global Clinical Trials Market for Dermatology, by Country/Region, 2022-2031 (USD Million)
  • Table 25 Global Clinical Trials Market for Orthopedic and Rheumatology, by Country/Region, 2022-2031 (USD Million)
  • Table 26 Global Clinical Trials Market for Rare Diseases, by Country/Region, 2022-2031 (USD Million)
  • Table 27 Global Clinical Trials Market for Gastroenterology & Hepatology, by Country/Region, 2022-2031 (USD Million)
  • Table 28 Global Clinical Trials Market for Respiratory, by Country/Region, 2022-2031 (USD Million)
  • Table 29 Global Clinical Trials Market for Women's Health, by Country/Region, 2022-2031 (USD Million)
  • Table 30 Global Clinical Trials Market for Urology, by Country/Region, 2022-2031 (USD Million)
  • Table 31 Global Clinical Trials Market for Mental Health, by Country/Region, 2022-2031 (USD Million)
  • Table 32 Global Clinical Trials Market for Ophthalmology, by Country/Region, 2022-2031 (USD Million)
  • Table 33 Global Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 34 Global Clinical Trials Market for Pharmaceuticals & Biotechnology Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 35 Global Clinical Trials Market for Medical Device Companies, by Country/Region, 2022-2031 (USD Million)
  • Table 36 Global Clinical Trials Market for Other End Users, by Country/Region, 2022-2031 (USD Million)
  • Table 37 Global Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 38 North America: Clinical Trials Market, by Country, 2022-2031 (USD Million)
  • Table 39 North America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 40 North America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 41 North America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 42 North America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 43 U.S.: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 44 U.S.: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 45 U.S.: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 46 U.S.: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 47 Canada: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 48 Canada: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 49 Canada: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 50 Canada: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 51 Europe: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 52 Europe: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 53 Europe: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 54 Europe: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 55 Europe: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 56 Germany: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 57 Germany: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 58 Germany: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 59 Germany: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 60 France: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 61 France: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 62 France: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 63 France: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 64 U.K.: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 65 U.K.: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 66 U.K.: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 67 U.K.: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 68 Italy: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 69 Italy: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 70 Italy: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 71 Italy: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 72 Spain: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 73 Spain: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 74 Spain: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 75 Spain: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 76 Poland: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 77 Poland: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 78 Poland: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 79 Poland: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 80 Belgium: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 81 Belgium: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 82 Belgium: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 83 Belgium: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 84 Rest of Europe: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 85 Rest of Europe: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 86 Rest of Europe: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 87 Rest of Europe: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 88 Asia-Pacific: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 89 Asia-Pacific: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 90 Asia-Pacific: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 91 Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 92 Asia-Pacific: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 93 Japan: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 94 Japan: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 95 Japan: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 96 Japan: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 97 China: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 98 China: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 99 China: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 100 China: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 101 India: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 102 India: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 103 India: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 104 India: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 105 Australia: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 106 Australia: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 107 Australia: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 108 Australia: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 109 South Korea: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 110 South Korea: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 111 South Korea: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 112 South Korea: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 113 Rest of Asia-Pacific: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 114 Rest of Asia-Pacific: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 115 Rest of Asia-Pacific: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 116 Rest of Asia-Pacific: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 117 Latin America: Clinical Trials Market, by Country/Region, 2022-2031 (USD Million)
  • Table 118 Latin America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 119 Latin America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 120 Latin America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 121 Latin America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 122 Brazil: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 123 Brazil: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 124 Brazil: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 125 Brazil: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 126 Mexico: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 127 Mexico: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 128 Mexico: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 129 Mexico: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 130 Rest of Latin America: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 131 Rest of Latin America: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 132 Rest of Latin America: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 133 Rest of Latin America: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 134 Middle East & Africa: Clinical Trials Market, by Phase, 2022-2031 (USD Million)
  • Table 135 Middle East & Africa: Clinical Trials Market, by Service Type, 2022-2031 (USD Million)
  • Table 136 Middle East & Africa: Clinical Trials Market, by Therapeutic Area, 2022-2031 (USD Million)
  • Table 137 Middle East & Africa: Clinical Trials Market, by End User, 2022-2031 (USD Million)
  • Table 138 Recent Developments, by Company, 2021-2024

LIST OF FIGURES

  • Figure 1 Research Process
  • Figure 2 Key Secondary Sources
  • Figure 3 Primary Research Techniques
  • Figure 4 Key Executives Interviewed
  • Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
  • Figure 6 Market Size Estimation
  • Figure 7 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
  • Figure 8 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
  • Figure 9 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
  • Figure 10 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 11 Global Clinical Trials Market, by Geography
  • Figure 12 Impact Analysis: Clinical Trials Market
  • Figure 13 Global Clinical Trials Market, by Phase, 2024 VS. 2031 (USD Million)
  • Figure 14 Global Clinical Trials Market, by Service Type, 2024 VS. 2031 (USD Million)
  • Figure 15 Global Clinical Trials Market, by Therapeutic Area, 2024 VS. 2031 (USD Million)
  • Figure 16 Global Clinical Trials Market, by End User, 2024 VS. 2031 (USD Million)
  • Figure 17 Global Clinical Trials Market, by Geography, 2024 VS. 2031 (USD Million)
  • Figure 18 North America: Clinical Trials Market Snapshot
  • Figure 19 Europe: Clinical Trials Market Snapshot
  • Figure 20 Asia-Pacific: Clinical Trials Market Snapshot
  • Figure 21 Latin America: Clinical Trials Market Snapshot
  • Figure 22 Key Growth Strategies Adopted by Leading Players, 2021-2024
  • Figure 23 Global Clinical Trials Market: Competitive Benchmarking, by Service Type
  • Figure 24 Global Clinical Trials Market: Competitive Benchmarking, by Geography
  • Figure 25 Global Clinical Trials Market: Competitive Dashboard
  • Figure 26 Global Clinical Trials Market: Market Share Analysis/ Market Ranking, By Players (2023)
  • Figure 27 Laboratory Corporation of America Holdings: Financial Overview (2023)
  • Figure 28 Medpace, Inc.: Financial Overview (2023)
  • Figure 29 Charles River Laboratories International, Inc.: Financial Overview (2023)
  • Figure 30 IQVIA Inc.: Financial Overview (2023)
  • Figure 31 WuXi AppTec Co., Ltd.: Financial Overview (2023)
  • Figure 32 Thermo Fisher Scientific Inc.: Financial Overview (2023)
  • Figure 33 Fortrea Inc.: Financial Overview (2022)
  • Figure 34 Linical USA, Inc.: Financial Overview (2023)